Cover Image
市場調查報告書

抗真菌劑市場分析:各類藥物 (唑,棘白菌素,多烯,丙烯基胺),各適應症 (皮膚絲狀菌症,麴菌症,念珠菌感染)的市場區隔預測

Antifungal Drugs Market Analysis By Drug Class (Azoles, Echinocandins, Polyenes, Allyamines), By Indication (Dermatophytosis, Aspergillosis, Candidiasis) And Segment Forecasts, 2014 - 2025

出版商 Grand View Research, Inc. 商品編碼 408955
出版日期 內容資訊 英文 110 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
抗真菌劑市場分析:各類藥物 (唑,棘白菌素,多烯,丙烯基胺),各適應症 (皮膚絲狀菌症,麴菌症,念珠菌感染)的市場區隔預測 Antifungal Drugs Market Analysis By Drug Class (Azoles, Echinocandins, Polyenes, Allyamines), By Indication (Dermatophytosis, Aspergillosis, Candidiasis) And Segment Forecasts, 2014 - 2025
出版日期: 2016年11月24日 內容資訊: 英文 110 Pages
簡介

本報告提供全球抗真菌劑市場相關調查,市場趨勢,各類藥物,各適應症,各地區趨勢,及打入市場的主要企業簡介等彙整資料。

第1章 調查方法

第2章 摘要整理

第3章 市場變動,趨勢,範圍

  • 市場區隔
    • 促進要素分析
    • 阻礙要素分析
  • 滲透、成長預測製圖
  • 大環境分析
  • 產業分析:波特

第4章 各類藥物預測、趨勢分析

  • 各類藥物趨勢分析
  • 棘白菌素
  • 多烯
  • 丙烯基胺
  • 其他

第5章 各適應症預測、趨勢分析

  • 各適應症趨勢分析
  • 皮膚絲狀菌症
  • 麴菌症
  • 念珠菌感染
  • 其他

第6章 各地區預測、趨勢分析

  • 各地區市場佔有率
  • 北美
  • 歐洲
  • 亞太地區
  • 南美
  • 中東、非洲

第7章 競爭環境

  • 策略架構
  • 市場進入分類
  • 企業簡介
目錄
Product Code: GVR-1-68038-293-8

The global antifungal drugs market was valued at USD 10.7 billion in 2015 and is expected to reach a value of USD 12.6 billion by 2025. The increasing incidence of fungal infections worldwide is the key contributing factor for the growth of the antifungal drugs market in the coming years. Rising adoption of immunosuppressive andantineoplastic agents, prosthetic devices and grafts, and broad-spectrum antibiotics have resulted in the increasing incidence of fungal infections in the recent years.

The growing geriatric population prone to infectious diseases and higher prevalence of chronic conditions, including HIV and cancer, are further contributing toward the rising demand for antifungals to treat opportunistic fungal infections over the forecast period. The large demand for these fungistatic agents is due to the nature of fungal infections, which are difficult to diagnose, yielding high mortality and morbidity rates.

Further Key Findings from the Study Suggest:

  • Echinocandins segment is anticipated to exhibit lucrative growth owing to their cell wall-specific fungicidal property coupled with their broad-spectrum activity against Aspergillus and Candida species without cross-resistance risks
  • Candidiasis indication segment is anticipated to witness the fastest CAGR over the forecast period due to the increasing drug resistance of the Candida speciesto Azoles
  • North America held the largest market share as of 2015, which is attributable to higher awareness levels pertaining to the treatment of fungal infection and presence of target diseases in the population
  • Asia pacific is predicted to exhibit the fastest growth due to improving healthcare facilities coupled with rising government initiatives to create awareness of infectious diseases amongst the population
  • The companies are focusing on the development of effective therapeutic agents for the treatment of systemic fungal infections in immune-compromised patients
  • Numerous ongoing public-private partnership agreements in the pharmaceutical industry for the development of novel therapeutics is predicted to provide this market with lucrative growth opportunities
  • For example, the public-private partnership, namely Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator is anticipated to provide USD 44 million in 2016 and around USD 350 million in the coming 5 years to boost the R&D pipeline
  • The partners involved in this partnership are the U.S. Department of Health and Human Services, the Antimicrobial Resistance Centrein England, and Boston University School of Law

Table of Contents

Chapter 1 Research Methodology & Scope

  • 1.1 Region Wise Market Calculation
    • 1.1.1 Region Wise Market: Base Estimates
    • 1.1.2 Global Market: CAGR Calculation
  • 1.2 Region based segment share calculation
  • 1.3 List of Secondary Sources

Chapter 2 Executive Summary

Chapter 3 Market VariabAllyamines, Trends& Scope

  • 3.1 Market segmentation & scope
    • 3.1.1 Market Driver Analysis
      • 3.1.1.1 Increasing incidences of fungal infections
      • 3.1.1.2 Increasing R&D pertaining to the development of novel drugs
      • 3.1.1.3 Increasing awareness levels
    • 3.1.2 Market Restraint Analysis
      • 3.1.2.1 Resistance to antifungal drugs
      • 3.1.2.2 Presence of generic competition
  • 3.2 Penetration & Growth Prospect Mapping
  • 3.3 Antifungal Drugs - PESTLE Analysis
  • 3.4 Industry Analysis - Porter's

Chapter 4 Market Categorization 1: Drug Class Estimates & Trend Analysis

  • 4.1 Antifungal Drugs Market: Drug Class Movement Analysis
  • 4.2 AzoAllyamines
    • 4.2.1 AzoAllyamines market, 2014 - 2025 (USD Million)
  • 4.3 Echinocandins
    • 4.3.1 Echinocandins market, 2014 - 2025 (USD Million)
  • 4.4 Polyenes
    • 4.4.1 Polyenes market, 2014 - 2025 (USD Million)
  • 4.5 Allylamines
    • 4.5.1 Allylamines market, 2014 - 2025 (USD Million)
  • 4.6 Others
    • 4.6.1 Others market, 2014 - 2025 (USD Million)

Chapter 5 Market Categorization : Indication Estimates & Trend Analysis

  • 5.1 Antifungal Drugs Market: indication Movement Analysis
  • 5.2 Dermatophytosis
    • 5.2.1 Dermatophytosis market, 2014 - 2025 (USD Million)
  • 5.3 Aspergillosis
    • 5.3.1 Aspergillosis market, 2014 - 2025 (USD Million)
  • 5.4 Candidiasis
    • 5.4.1 Candidiasis market, 2014 - 2025 (USD Million)
  • 5.5 Others
    • 5.5.1 Others market, 2014 - 2025 (USD Million)

Chapter 6 Market Categorization : Regional Estimates & Trend Analysis, by Drug Class and Indications

  • 6.1 Antifungal Drugs market share by region, 2015 & 2024
  • 6.2 North America
    • 6.2.1 North America antifungal drugs market, 2014 - 2025 (USD Million)
    • 6.2.2 U.S.
      • 6.2.2.1 U.S. antifungal drugs market, 2014 - 2025 (USD Million)
    • 6.2.3 Canada
      • 6.2.3.1 Canada antifungal drugs market, 2014 - 2025 (USD Million)
  • 6.3 Europe
    • 6.3.1 Europe antifungal drugs market, 2014 - 2025 (USD Million)
    • 6.3.2 UK
      • 6.3.2.1 UK antifungal drugs market, 2014 - 2025 (USD Million)
    • 6.3.3 Germany
      • 6.3.3.1 Germany antifungal drugs market, 2014 - 2025 (USD Million)
  • 6.4 Asia Pacific
    • 6.4.1 Asia Pacific antifungal drugs market, 2014 - 2025 (USD Million)
    • 6.4.2 Japan
      • 6.4.2.1 Japan antifungal drugs market, 2014 - 2025 (USD Million)
    • 6.4.3 China
      • 6.4.3.1 China antifungal drugs market, 2014 - 2025 (USD Million)
    • 6.4.4 India
      • 6.4.4.1 India antifungal drugs market, 2014 - 2025 (USD Million)
  • 6.5 Latin America
    • 6.5.1 Latin America antifungal drugs market, 2014 - 2025 (USD Million)
    • 6.5.2 Brazil
      • 6.5.2.1 Brazil antifungal drugs market, 2014 - 2025 (USD Million)
    • 6.5.3 Mexico
      • 6.5.3.1 Mexico antifungal drugs market, 2014 - 2025 (USD Million)
  • 6.6 MEA
    • 6.6.1 MEA antifungal drugs market, 2014 - 2025 (USD Million)
    • 6.6.2 South Africa
      • 6.6.2.1 South Africa antifungal drugs market, 2014 - 2025 (USD Million)

Chapter 7 Competitive Landscape

  • 7.1 Strategy framework
  • 7.2 Market participation categorization
  • 7.3 Company Profiles
    • 7.3.1 Novartis
      • 7.3.1.1 Company Overview
      • 7.3.1.2 Financial Performance
      • 7.3.1.3 Product Benchmarking
      • 7.3.1.4 Strategic Initiatives
    • 7.3.2 Pfizer Inc.
      • 7.3.2.1 Company Overview
      • 7.3.2.2 Financial Performance
      • 7.3.2.3 Product Benchmarking
      • 7.3.2.4 Strategic Initiatives
    • 7.3.3 Bayer Healthcare
      • 7.3.3.1 Company Overview
      • 7.3.3.2 Financial Performance
      • 7.3.3.3 ProductBenchmarking
      • 7.3.3.4 Strategic Initiatives
    • 7.3.4 Sanofi-Aventis
      • 7.3.4.1 Company Overview
      • 7.3.4.2 Financial Performance
      • 7.3.4.3 Product Benchmarking
      • 7.3.4.4 Strategic Initiatives
    • 7.3.5 Merck & Co. Inc.
      • 7.3.5.1 Company Overview
      • 7.3.5.2 Financial Performance
      • 7.3.5.3 Product Benchmarking
      • 7.3.5.4 Strategic Initiatives
    • 7.3.6 GlaxoSmithKline
      • 7.3.6.1 Company Overview
      • 7.3.6.2 Financial Performance
      • 7.3.6.3 Product Benchmarking
    • 7.3.7 Abbott Laboratories
      • 7.3.7.1 Company Overview
      • 7.3.7.2 Financial Performance
      • 7.3.7.3 Product Benchmarking
      • 7.3.7.4 Strategic Initiatives
    • 7.3.8 Glenmark Pharmaceuticals Ltd
      • 7.3.8.1 Company Overview
      • 7.3.8.2 Financial Performance
      • 7.3.8.3 Product Benchmarking
      • 7.3.8.4 Strategic Initiatives
    • 7.3.9 Enzon Pharmaceuticals
      • 7.3.9.1 Company Overview
      • 7.3.9.2 Financial Performance
      • 7.3.9.3 Product Benchmarking
      • 7.3.9.4 Strategic Initiatives
    • 7.3.10 ID Sigma-Aldrich Corporation
      • 7.3.10.1 Company Overview
      • 7.3.10.2 Financial Performance
      • 7.3.10.3 Product Benchmarking
      • 7.3.10.4 Strategic Initiatives
    • 7.3.11 Astellas Pharma Inc
      • 7.3.11.1 Company Overview
      • 7.3.11.2 Financial Performance
      • 7.3.11.3 Product Benchmarking
      • 7.3.11.4 Strategic Initiatives

List of Tables

  • TABLE 1 North America antifungal drugs market, by drug class, 2014 - 2025 (USD Million)
  • TABLE 2 North America antifungal drugs market, by Indications, 2014 - 2025 (USD Million)
  • TABLE 3 U.S. antifungal drugs market, by drug class, 2014 - 2025 (USD Million)
  • TABLE 4 U.S. antifungal drugs market, by Indications, 2014 - 2025 (USD Million)
  • TABLE 5 Canada antifungal drugs market, by drug class, 2014 - 2025 (USD Million)
  • TABLE 6 Canada antifungal drugs market, by Indications, 2014 - 2025 (USD Million)
  • TABLE 7 Europe antifungal drugs market, by drug class, 2014 - 2025 (USD Million)
  • TABLE 8 Europe antifungal drugs market, by Indications, 2014 - 2025 (USD Million)
  • TABLE 9 UK antifungal drugs market, by drug class, 2014 - 2025 (USD Million)
  • TABLE 10 UK antifungal drugs market, by Indications, 2014 - 2025 (USD Million)
  • TABLE 11 Germany antifungal drugs market, by drug class, 2014 - 2025 (USD Million)
  • TABLE 12 Germany antifungal drugs market, by Indications, 2014 - 2025 (USD Million)
  • TABLE 13 Asia Pacific antifungal drugs market, by drug class, 2014 - 2025 (USD Million)
  • TABLE 14 Asia Pacific antifungal drugs market, by Indications, 2014 - 2025 (USD Million)
  • TABLE 15 Japan antifungal drugs market, by drug class, 2014 - 2025 (USD Million)
  • TABLE 16 Japan antifungal drugs market, by Indications, 2014 - 2025 (USD Million)
  • TABLE 17 China antifungal drugs market, by drug class, 2014 - 2025 (USD Million)
  • TABLE 18 China antifungal drugs market, by Indications, 2014 - 2025 (USD Million)
  • TABLE 19 India antifungal drugs market, by drug class, 2014 - 2025 (USD Million)
  • TABLE 20 India antifungal drugs market, by Indications, 2014 - 2025 (USD Million)
  • TABLE 21 Latin America antifungal drugs market, by drug class, 2014 - 2025 (USD Million)
  • TABLE 22 Latin America antifungal drugs market, by Indications, 2014 - 2025 (USD Million)
  • TABLE 23 Brazil antifungal drugs market, by drug class, 2014 - 2025 (USD Million)
  • TABLE 24 Brazil antifungal drugs market, by Indications, 2014 - 2025 (USD Million)
  • TABLE 25 Mexico antifungal drugs market, by drug class, 2014 - 2025 (USD Million)
  • TABLE 26 Mexico antifungal drugs market, by Indications, 2014 - 2025 (USD Million)
  • TABLE 27 MEA antifungal drugs market, by drug class, 2014 - 2025 (USD Million)
  • TABLE 28 MEA antifungal drugs market, by Indications, 2014 - 2025 (USD Million)
  • TABLE 29 South Africa antifungal drugs market, by drug class, 2014 - 2025 (USD Million)
  • TABLE 30 South Africa antifungal drugs market, by Indications, 2014 - 2025 (USD Million)

List of Figures

  • FIG. 1 Market summary
  • FIG. 2 Market trends & outlook
  • FIG. 3 Market segmentation & scope
  • FIG. 4 Market driver relevance analysis (Current & future impact)
  • FIG. 5 U.S. FDA ADR reports, 2006-2015
  • FIG. 6 Market restraint relevance analysis (Current & future impact)
  • FIG. 7 Penetration & Growth Prospect Mapping
  • FIG. 8 Antifungal Drugs PESTLE Analysis
  • FIG. 9 Porter's Five Forces Analysis
  • FIG. 10 Antifungal Drugs market drug class outlook key takeaways
  • FIG. 11 Antifungal Drugs market: Drug class movement analysis
  • FIG. 12 AzoAllyamines market, 2014 - 2025 (USD Million)
  • FIG. 13 Echinocandins market, 2014 - 2025 (USD Million)
  • FIG. 14 Polyenes market, 2014 - 2025 (USD Million)
  • FIG. 15 Allylamines market, 2014 - 2025 (USD Million)
  • FIG. 16 Others market, 2014 - 2025 (USD Million)
  • FIG. 17 Antifungal Drugs market indication outlook key takeaways
  • FIG. 18 Antifungal Drugs market: Indications movement analysis
  • FIG. 19 Dermatophytosis market, 2014 - 2025 (USD Million)
  • FIG. 20 Aspergillosis market, 2014 - 2025 (USD Million)
  • FIG. 21 Candidiasis market, 2014 - 2025 (USD Million)
  • FIG. 22 Others market, 2014 - 2025 (USD Million)
  • FIG. 23 Regional marketplace: Key takeaways
  • FIG. 24 Regional outlook, 2015 & 2024
  • FIG. 25 North America antifungal drugs market, 2014 - 2025 (USD Million)
  • FIG. 26 U.S. antifungal drugs market, 2014 - 2025 (USD Million)
  • FIG. 27 Canada antifungal drugs market, 2014 - 2025 (USD Million)
  • FIG. 28 Europe antifungal drugs market, 2014 - 2025 (USD Million)
  • FIG. 29 UK antifungal drugs market, 2014 - 2025 (USD Million)
  • FIG. 30 Germany antifungal drugs market, 2014 - 2025 (USD Million)
  • FIG. 31 Asia Pacific antifungal drugs market, 2014 - 2025 (USD Million)
  • FIG. 32 Japan antifungal drugs market, 2014 - 2025 (USD Million)
  • FIG. 33 China antifungal drugs market, 2014 - 2025 (USD Million)
  • FIG. 34 India antifungal drugs market, 2014 - 2025 (USD Million)
  • FIG. 35 Latin America antifungal drugs market, 2014 - 2025 (USD Million)
  • FIG. 36 Brazil antifungal drugs market, 2014 - 2025 (USD Million)
  • FIG. 37 Mexico antifungal drugs market, 2014 - 2025 (USD Million)
  • FIG. 38 MEA antifungal drugs market, 2014 - 2025 (USD Million)
  • FIG. 39 South Africa antifungal drugs market, 2014 - 2025 (USD Million)
  • FIG. 40 Strategy framework
  • FIG. 41 Participant categorization
Back to Top